Securian Asset Management Inc. Cuts Holdings in Boston Scientific Co. (NYSE:BSX)

Securian Asset Management Inc. trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 11.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,705 shares of the medical equipment provider's stock after selling 12,369 shares during the period. Securian Asset Management Inc.'s holdings in Boston Scientific were worth $5,359,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. NorthRock Partners LLC raised its stake in shares of Boston Scientific by 13.9% in the fourth quarter. NorthRock Partners LLC now owns 8,570 shares of the medical equipment provider's stock valued at $495,000 after buying an additional 1,048 shares during the period. Navellier & Associates Inc. purchased a new position in shares of Boston Scientific in the fourth quarter valued at $273,000. Panagora Asset Management Inc. grew its position in shares of Boston Scientific by 4.3% in the fourth quarter. Panagora Asset Management Inc. now owns 61,679 shares of the medical equipment provider's stock valued at $3,566,000 after purchasing an additional 2,535 shares in the last quarter. EFG Asset Management North America Corp. grew its position in shares of Boston Scientific by 118.3% in the fourth quarter. EFG Asset Management North America Corp. now owns 38,528 shares of the medical equipment provider's stock valued at $2,228,000 after purchasing an additional 20,880 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its position in shares of Boston Scientific by 1.7% in the fourth quarter. Quadrant Capital Group LLC now owns 13,358 shares of the medical equipment provider's stock valued at $772,000 after purchasing an additional 221 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares of the company's stock, valued at $17,883,756.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Edward J. Ludwig sold 9,818 shares of the stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the transaction, the director now directly owns 41,374 shares of the company's stock, valued at $3,032,300.46. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Daniel J. Brennan sold 13,662 shares of the firm's stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total value of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares of the company's stock, valued at approximately $17,883,756.12. The disclosure for this sale can be found here. Insiders have sold 88,261 shares of company stock valued at $6,185,929 over the last 90 days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX traded up $0.10 on Friday, reaching $74.65. The company's stock had a trading volume of 6,978,299 shares, compared to its average volume of 7,070,820. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The stock has a market capitalization of $109.52 billion, a P/E ratio of 62.73, a PEG ratio of 2.57 and a beta of 0.77. The stock's 50 day simple moving average is $69.73 and its two-hundred day simple moving average is $62.89. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $74.94.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion for the quarter, compared to the consensus estimate of $3.68 billion. Research analysts forecast that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Evercore ISI lifted their price target on Boston Scientific from $72.00 to $78.00 and gave the company an "outperform" rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their price target on Boston Scientific from $63.00 to $73.00 and gave the company a "hold" rating in a research report on Thursday, April 25th. Mizuho lifted their price target on Boston Scientific from $85.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday. Royal Bank of Canada boosted their target price on Boston Scientific from $78.00 to $82.00 and gave the stock an "outperform" rating in a research report on Thursday, April 25th. Finally, UBS Group boosted their target price on Boston Scientific from $74.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $75.32.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.